Anti-(human Respiratory Syncytial Virus Fusion Glycoprotein F0 (protein F))human Monoclonal Antibody.gamma.1 Heavy Chain (1-456) (human Vh (homo Sapiens Ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo Sapiens Ighg1*03
Anti-(human Respiratory Syncytial Virus Fusion Glycoprotein F0 (protein F))human Monoclonal Antibody.gamma.1 Heavy Chain (1-456) (human Vh (homo Sapiens Ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo Sapiens Ighg1*03 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(human Respiratory Syncytial Virus Fusion Glycoprotein F0 (protein F))human Monoclonal Antibody.gamma.1 Heavy Chain (1-456) (human Vh (homo Sapiens Ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo Sapiens Ighg1*03 is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI) in High-risk Children).
| Trade Name | Anti-(human Respiratory Syncytial Virus Fusion Glycoprotein F0 (protein F))human Monoclonal Antibody.gamma.1 Heavy Chain (1-456) (human Vh (homo Sapiens Ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo Sapiens Ighg1*03 |
| Generic | Nirsevimab |
| Nirsevimab Other Names | Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03, Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897 .gamma.1-chain), disulfide with monoclonal med18897 .kappa.-chain, dimer, Nirsevimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
